BioPharma « Terug naar discussie overzicht

Xoma

450 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ... 19 20 21 22 23 » | Laatste

Omlaag ↓

[verwijderd] 28 mei 2009 09:17

quote:
1gustaaf schreef:
[quote=domus muris]
[quote=1gustaaf]
hm..lijkt meer op Mesopotamisch.
G
[/quote]

Jij moet je wel laten bijscholen Gustaaf. Het is echt Chinees. Vraag maar naar na bij het plaatselijke restaurant.
[/quote]
Ach ja, Domus, ik moet die tekst natuurlijk ook van rechts naar links lezen. Dom van mij.
G

Kijk, jij snapt het!
Misschien is het ook wel een beetje Xomatisch.

[verwijderd] 4 juni 2009 18:31

Als Psycho hem niet naar boven haalt, dan doe ik maar: $ 1.08 +27%

[verwijderd] 4 juni 2009 18:35

quote:
tonpa schreef:
Als Psycho hem niet naar boven haalt, dan doe ik maar: $ 1.08 +27%

Wat zeg ik +33% $ 1.13

[verwijderd] 4 juni 2009 19:48

Kom net binnen...............

+37% op 1,17 (omzet 15.000.000 aandelen......)

Dit zijn waarschijnlijk de redenen voor de stijging:

1. XOMA will announce XOMA052 two phase I results at June-5-9
--very positive

2. XOMA052 phase II trial & parterns

3. Royalty from CIMZIA ($15M) will fill Raptiva $15M

4. Recently public off at $0.85 per share

++ XOMA to Present At Annual Needham Life Sciences Conference On June 10, 2009

P.

jip banaan! 4 juni 2009 21:36

Maar weer verkocht.

[verwijderd] 4 juni 2009 21:42

quote:
jip banaan! schreef:
Maar weer verkocht.

Ik ook. Voor $ 1.15 en jij?

jip banaan! 4 juni 2009 21:56

quote:
domus muris schreef:
[quote=jip banaan!]
Maar weer verkocht.
[/quote]

Ik ook. Voor $ 1.15 en jij?

1.13 Domus, winst is winst.

[verwijderd] 4 juni 2009 21:58

quote:
jip banaan! schreef:
[quote=domus muris]
[quote=jip banaan!]
Maar weer verkocht.
[/quote]

Ik ook. Voor $ 1.15 en jij?
[/quote]

1.13 Domus, winst is winst.

Ja,ja, en jij had ze goedkoper dan ik, Jip.

[verwijderd] 4 juni 2009 22:03

Slot: $1,18
++33 cents (38,8%)
25.000.000 aandelen

P.

spyfly 4 juni 2009 22:30

Heb ze ook verkocht voor 1.13, in 3 dagen toch weer 40%

[verwijderd] 4 juni 2009 22:36

quote:
spyfly schreef:
Heb ze ook verkocht voor 1.13, in 3 dagen toch weer 40%

Leuk! ik had ze vanaf 15-5 en moest met iets minder genoegen nemen. Maar ik ben tevreden. Had een paar dagen ervoor ook een vette vis met Xoma.
De zittenblijvers succes! Ik denk dat er nog wel meer onder de kurk zit.

[verwijderd] 4 juni 2009 22:39

quote:
domus muris schreef:
[quote=spyfly]
Heb ze ook verkocht voor 1.13, in 3 dagen toch weer 40%
[/quote]

De zittenblijvers succes! Ik denk dat er nog wel meer onder de kurk zit.

Ik denk, als ik het zeldzaam hoge volume zie, dat er snel een partner dan wel een buy-out komt.

En dan ontkurk ik wel een stevig Pomerolletje.

P.

[verwijderd] 4 juni 2009 22:50

Nu: $1,26

Belooft wat voor morgen..............

P.

[verwijderd] 5 juni 2009 08:27

quote:
psycho-pharma schreef:
Slot: $1,18
++33 cents (38,8%)
25.000.000 aandelen

P.

After Hours
Last: $ 1.38
High: $ 1.39
Volume: 1,715,468

P.

[verwijderd] 5 juni 2009 14:05

$ 1.43 bij 172.000 stuks

[verwijderd] 5 juni 2009 15:07

BERKELEY, Calif., June 5, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of antibody therapeutics, today announced that it has entered into a definitive agreement with certain institutional investors to sell 10,434,782 units, with each unit consisting of one of the Company's common shares and a warrant to purchase 0.50 of a common share, for gross proceeds of approximately $12.0 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investor has agreed to purchase the units at a purchase price of $1.15 per unit.

Helaas nu onderuit..even.........?

[verwijderd] 5 juni 2009 15:16

Prijs was 1.15 en daar zit het nu op. Ik verwacht geen grote daling beneden het slot van gisteren, tenzij de shorters bloed ruiken.

P.

[verwijderd] 6 juni 2009 23:34

De nieuwe insteek richting diabetes 2 lijkt veelbelovend.

XOMA 052 Clinical Results Support Novel Anti-Inflammatory Approach to Type 2 Diabetes Treatment

Clinical Data Presented At American Diabetes Association 69th Scientific Sessions

BERKELEY, Calif., Jun 6, 2009 (GlobeNewswire via COMTEX News Network) -

The studies demonstrated:

* XOMA 052 was well-tolerated, with no drug or dose-related
serious adverse events or injection site reactions.
* Improvement in insulin production and secretion for patients
receiving XOMA 052 for as long as 91 days.
* A durable reduction of high sensitivity C-Reactive Protein
(hsCRP), a standard measure of inflammation which is
associated with an increased risk of cardiovascular events,
for as long as 91 days following a single infusion of
XOMA 052.
* Consistent reduction in glycosylated hemoglobin(HbA1c), a
standard measure of average glucose control over a
three-month period for XOMA 052-treated patients as compared
to placebo for as long as 91 days.
* A favorable immunologic profile, with XOMA 052 having
positive effects on reducing the levels of pro-inflammatory
cytokines such as TNF-alpha, IL-6 and IL-1alpha. In addition,
XOMA 052 did not demonstrate a suppressive effect on
protective cytokines including interferon-alpha and IL-1
receptor antagonist, which are needed for infection control
and host defense.
* A pharmacokinetic profile, including a 22 day half-life,
which suggests the potential for XOMA 052 dosing at monthly
or less frequent intervals.

"It is well-recognized that IL-1 beta levels are up-regulated in response to elevated glucose. This causes an auto-inflammatory process in insulin-producing cells that can lead to their death and reduced insulin secretion," said Dr. Donath. "If, as we hypothesize, the inhibition of IL-1 beta improves the condition of insulin-producing cells in patients by breaking the vicious cycle of glucotoxicity, the implications would be very promising for the treatment of the disease."

"We continue to develop evidence supporting one of the most significant potential medical advances in decades -- a move from insulin therapy to anti-inflammatory treatment of patients with Type 2 diabetes. Our results have provided not only the safety data that is typical in a Phase 1 trial but also encouraging signs of biological activity," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "Recently, our first U.S. patent covering XOMA 052 issued and we completed enrollment of the Phase 1 program with 98 patients. We look forward to initiating Phase 2 trials in the third quarter of 2009."

"These results demonstrate the potential for XOMA 052 to offer an entirely new approach for Type 2 diabetes patients by targeting inflammation, rather than current treatments that force more insulin out of "tired" pancreatic beta cells or make peripheral cells more sensitive to insulin," said Patrick J. Scannon, M.D., Ph.D., XOMA's Executive Vice President and Chief Medical Officer. "Further, some studies have shown that certain diabetes medications may increase the risk of cardiovascular events in a population already at risk due to obesity or other factors. The positive effect of XOMA 052 on reducing levels of the hsCRP cardiovascular risk marker in these trials suggests its potential for a beneficial systemic anti-inflammatory outcome, and warrants further investigation in additional trials."

investors.xoma.com/releasedetail.cfm?...

P.

[verwijderd] 6 juni 2009 23:41

>>>>>>>>>>>>>"We continue to develop evidence supporting one of the most significant potential medical advances in decades -- a move from insulin therapy to anti-inflammatory treatment of patients with Type 2 diabetes. Our results have provided not only the safety data that is typical in a Phase 1 trial but also encouraging signs of biological activity," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. <<<

""....one of the most significant potential medical advances in decades""

Klinkt wel aardig.

Ik hou ze nog even.............

P.

[verwijderd] 8 juni 2009 17:11

+ 20%
14.000.000 aandelen reeds.

P.

450 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ... 19 20 21 22 23 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 946,61 +0,03 +0,00% 14 feb


Germany40^	22.504,40	-0,04%
BEL 20	4.396,58	-0,82%
Europe50^	5.480,25	-0,24%
US30^	44.524,90	0,00%
Nasd100^	22.109,50	0,00%
US500^	6.112,09	0,00%
Japan225^	39.114,70	0,00%
Gold spot	2.882,65	0,00%
EUR/USD	1,0493	+0,24%
WTI	70,68	0,00%